

Glycostem donates funding to the Acute Leukemia Advocates Network and Leukaemia Care

Oss, the Netherlands – 11th May 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, announced the donation to the Acute Leukemia Advocates Network (ALAN) and to Leukaemia Care.

“We care for the health and well-being of blood cancer patients and their families.” said Troels Jordansen, CEO of Glycostem. “On top of our own efforts in developing and clinical testing our own NK cell therapy oNKord[®], we are glad to support ALAN and Leukaemia Care. These donations also embrace part of our vision and mission, to cover the strong unmet medical needs of cancer patients and look after patients, staff and the environment.”

The Acute Leukemia Advocates Network (ALAN) is an independent global network of patient organisations, dedicated to changing outcomes of patients with all types of acute leukemias by strengthening patient advocacy in that area. Leukaemia Care is a UK national blood cancer support charity, who are dedicated to ensuring that anyone affected by blood cancer receives the right information, advice and support.

About Glycostem

Netherlands-based Glycostem Therapeutics B.V., a clinical stage biotech company, developing allogeneic cellular immunotherapies to treat several types of cancer. By harnessing the power of stem cell-derived Natural Killer (NK) cells, Glycostem’s products are a safe alternative to CAR-T-cells. Glycostem’s lead product, oNKord[®], is manufactured from allogeneic raw material and is available off-the-shelf. Thanks to its nine patent families, longstanding technical expertise and resources, as well as ‘Orphan Drug Designation’, Glycostem has secured a leadership position in the global NK-cell market with off-the-shelf products.

oNKord[®] is produced in a closed system (uNiK[™]) in Glycostem’s state-of-the-art and GMP (Good Manufacturing Practice) licensed production facility in the Netherlands, from which it can be distributed globally. The production technology includes *ex vivo* generation of high numbers of NK-cells with a high degree of purity for clinical applications. oNKord[®] successfully passed phase I clinical trial (elderly and frail AML - Acute Myeloid Leukemia - patients), providing solid safety data and strong indication of clinical activity, including response on MRD (Minimal Residual Disease). A phase I/IIa (pivotal) clinical trial is on-going to evaluate the safety and efficacy of oNKord[®] in patients with AML. Glycostem is furthermore developing a range of CAR-NK and TCR-NK products in-house and in cooperation with global partners.

oNKord[®] is a registered trademark of Glycostem in the US and Europe. viveNK[™] and uNiK[™] are pending trademarks of Glycostem.

Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com – www.Glycostem.com

Glycostem Therapeutics BV

Troels Jordansen

Tel +31 6 1834 5326

Troels@Glycostem.com

Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com – www.Glycostem.com